Literature DB >> 24385335

Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.

Connie M Rhee1, Miklos Z Molnar1, Wei Ling Lau2, Vanessa Ravel3, Csaba P Kovesdy2, Rajnish Mehrotra3, Kamyar Kalantar-Zadeh1.   

Abstract

BACKGROUND: In hemodialysis (HD) patients, serum alkaline phosphatase (ALP) and parathyroid hormone (PTH) derangements are associated with mortality, but outcome-predictability using ALP and PTH in peritoneal dialysis (PD) patients remains uncertain.
METHODS: In a cohort of 9244 adult PD patients from a large national dialysis organization (entry period 2001 - 2006, with follow-up through 2009), we used multivariable Cox models adjusted for case-mix and laboratory covariates to examine the associations of time-averaged ALP and PTH with all-cause mortality. We then compared mortality-predictability using ALP and PTH in 9244 PD and 99 323 HD patients.
RESULTS: In PD patients, ALP concentrations exceeding 150 U/L were associated with increased mortality (reference ALP: 70 to <90 U/L). Hazard ratios (HRs) and 95% confidence intervals (CIs) were 1.18 (1.03 to 1.36), 1.27 (1.08 to 1.50), 1.49 (1.23 to 1.79), and 1.35 (1.19 to 1.53) for ALP concentrations of 150 to <170 U/L, 170 to <190 U/L, 190 to <210 U/L, and ≥210 U/L respectively. In contrast, we observed a U-shaped association between PTH concentration and death risk in PD patients, with PTH concentrations of less than 200 pg/mL and 700 pg/mL or more associated with increased mortality (reference PTH: 200 to <300 pg/mL). Hazard ratios and 95% CIs were 1.25 (1.12 to 1.41), 1.12 (1.02 to 1.23), 1.06 (0.96 to 1.18), 1.09 (0.97 to 1.24), 1.12 (0.97 to 1.29), 1.18 (0.99 to 1.40), and 1.23 (1.09 to 1.38) for PTH concentrations of <100 pg/mL, 100 to <200 pg/mL, 300 to <400 pg/mL, 400 to <500 pg/mL, 500 to <600 pg/mL, 600 to <700 pg/mL, and ≥700 pg/mL respectively. Compared with PD patients having serum concentrations of ALP and PTH within reference ranges, patients on HD experienced increased mortality across all ALP and PTH concentrations, particularly those in the lowest and highest categories.
CONCLUSIONS: In summary, higher ALP concentrations are associated with increased mortality, and lower and higher PTH concentrations are both associated with death risk in PD patients. The utility of ALP in the management of chronic kidney disease mineral bone disorders in PD patients warrants further study.
Copyright © 2014 International Society for Peritoneal Dialysis.

Entities:  

Keywords:  CKD mineral bone disorders; alkaline phosphatase; parathyroid hormone

Mesh:

Substances:

Year:  2014        PMID: 24385335      PMCID: PMC4269499          DOI: 10.3747/pdi.2013.00110

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  55 in total

1.  Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study.

Authors:  Shani Shastri; Navdeep Tangri; Hocine Tighiouart; Gerald J Beck; Panagiotis Vlagopoulos; Daniel Ornt; Garabed Eknoyan; John W Kusek; Charles Herzog; Alfred K Cheung; Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 8.237

2.  Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone.

Authors:  M Coco; H Rush
Journal:  Am J Kidney Dis       Date:  2000-12       Impact factor: 8.860

3.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

4.  Rebuttal: the case for routine parathyroid hormone monitoring.

Authors:  David J A Goldsmith
Journal:  Clin J Am Soc Nephrol       Date:  2012-11-15       Impact factor: 8.237

5.  Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.

Authors:  Deborah L Regidor; Csaba P Kovesdy; Rajnish Mehrotra; Mehdi Rambod; Jennie Jing; Charles J McAllister; David Van Wyck; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

6.  Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification.

Authors:  K A Lomashvili; P Garg; S Narisawa; J L Millan; W C O'Neill
Journal:  Kidney Int       Date:  2008-02-20       Impact factor: 10.612

7.  Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease.

Authors:  Mhairi K Sigrist; Maarten W Taal; Peter Bungay; Christopher W McIntyre
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-10       Impact factor: 8.237

8.  Risk of adynamic bone disease in dialyzed patients.

Authors:  H H Malluche; M C Monier-Faugere
Journal:  Kidney Int Suppl       Date:  1992-10       Impact factor: 10.545

9.  Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients.

Authors:  Ronney Shantouf; Csaba P Kovesdy; Youngmee Kim; Naser Ahmadi; Amanda Luna; Claudia Luna; Mehdi Rambod; Allen R Nissenson; Matthew J Budoff; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 8.237

10.  Role for alkaline phosphatase as an inducer of vascular calcification in renal failure?

Authors:  M Schoppet; C M Shanahan
Journal:  Kidney Int       Date:  2008-05       Impact factor: 10.612

View more
  21 in total

Review 1.  Does PTH offer additive value to ALP measurement in assessing CKD-MBD?

Authors:  Edmund J Lamb; Michael P Delaney
Journal:  Perit Dial Int       Date:  2014 Nov-Dec       Impact factor: 1.756

Review 2.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

Review 3.  Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures.

Authors:  Wei Ling Lau; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2014-04-15       Impact factor: 5.992

4.  Metabolic status and personality affect the prognosis of patients with continuous ambulatory peritoneal dialysis.

Authors:  Yan Liu; Hao Zhang; Ke Zhang; Jun Liu; Liuchan Zhou; Xiangping Liao; Jianzhao Cheng; Xiaohua Deng; Zhiming Xia
Journal:  Int J Clin Exp Med       Date:  2015-01-15

5.  Liver Function Enzymes are Potential Predictive Markers for Kidney Allograft Dysfunction.

Authors:  Alakesh Bera; Eric Russ; Rahul M Jindal; Maura A Watson; Robert Nee; Ofer Eidelman; John Karaian; Harvey B Pollard; Meera Srivastava
Journal:  Adv J Urol Nephrol       Date:  2020-03-03

6.  Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism.

Authors:  Melissa Soohoo; Yoshitsugu Obi; Matthew B Rivara; Scott V Adams; Wei Ling Lau; Connie M Rhee; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Onyebuchi A Arah; Rajnish Mehrotra; Elani Streja
Journal:  Am J Nephrol       Date:  2022-02-28       Impact factor: 4.605

Review 7.  Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.

Authors:  S N Salam; A Khwaja; M E Wilkie
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

8.  High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve?

Authors:  Rafael Weissheimer; Sergio Gardano Elias Bucharles; Cesar Augusto Madid Truyts; Vanda Jorgetti; Ana Elizabeth Figueiredo; Pasqual Barrett; Marcia Olandoski; Roberto Pecoits-Filho; Thyago Proença de Moraes
Journal:  J Bras Nefrol       Date:  2021 Apr-Jun

9.  Predicting one-year mortality in peritoneal dialysis patients: an analysis of the China Peritoneal Dialysis Registry.

Authors:  Xue-Ying Cao; Jian-Hui Zhou; Guang-Yan Cai; Ni-Na Tan; Jing Huang; Xiang-Cheng Xie; Li Tang; Xiang-Mei Chen
Journal:  Int J Med Sci       Date:  2015-05-01       Impact factor: 3.738

10.  Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Authors:  Sunil V Badve; Lei Zhang; Jeff S Coombes; Elaine M Pascoe; Alan Cass; Philip Clarke; Paolo Ferrari; Stephen P McDonald; Alicia T Morrish; Eugenie Pedagogos; Vlado Perkovic; Donna Reidlinger; Anish Scaria; Rowan Walker; Liza A Vergara; Carmel M Hawley; David W Johnson
Journal:  Can J Kidney Health Dis       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.